Novanta Inc. (NOVT) — Research Brief as of 2026-10-24

Recent Catalysts (roughly July–October 2026)

Q2 2026 earnings (reported August 5–6, 2026) — the dominant recent catalyst. Novanta reported second-quarter revenue of US$265.81 million, up 10.30% year-over-year, beating consensus of ~US$262.3 million. Adjusted (non-GAAP) diluted EPS came in at US$0.89 against consensus of US$0.83, while GAAP diluted EPS was US$0.30 versus US$0.12 a year earlier, and operating income and adjusted EBITDA both expanded. Management also completed its acquisition of Riverpoint Medical in the quarter and raised full-year guidance (reported reported sales growth of 10%, organic of 9%). [9][16][18]